Pharmaceutical Name
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine, Modified Live Virus

• High antigenic mass (titer), low passage parvovirus vaccine.

• Canine vaccine containing parvovirus type 2b, the most prevalent field strain of parvovirus.

• Canine parvovirus type 2b protects against all field strains currently seen.

• Overrides maternal antibodies in young puppies. Primary vaccination may begin as early as 6 weeks. Last dose may be given at 12 weeks of age.

• No reversion to virulence.

• Onderstepoort-type distemper strain, proven efficacious for over 50 years.
  Lyophilized L. canicola and L. icterohaemorrhagiae provide broad protection with added stability and convenience. 

Indications
GALAXY^® DA2PPv+Cv is a combination vaccine that unites the benefits of Galaxy® DA2PPv and Galaxy® Cv in one vaccination.
Galaxy^® DA2PPv is a modified live virus vaccine for the vaccination of healthy dogs against canine distemper, adenovirus type 2, hepatitis, parainfluenza and parvovirus.
Galaxy^® Cv (feline enteric coronavirus) is a killed virus vaccine for the vaccination of healthy dogs against disease caused by canine coronavirus infection.

Dosage
For further information including dose rate and complete directions and warnings, please see the Product Label by clicking here.
 
Galaxy^® DA2PPv+Cv is a registered trademark of Schering-Plough Animal Health Corporation.